Meta-Analysis of the Effectiveness of Sofosbuvir-Based Regimens in Treating Hepatitis C Genotype 3

Hafsa Siddique, Syed Sufyan Tariq, Syed Parvez Asghar, Muhammad Faisal Fahim

ABSTRACT

Hepatitis C virus (HCV) is an RNA virus with seven primary genotypes. It is highly prevalent in Pakistan, especially genotype 3. HCV infection can progress to a chronic state with further complications. Direct-acting antiviral agents (DAAV) were introduced in 2014 as a treatment option, some of which include Sofosbuvir (SOF), Daclatasvir (DCV), Velpatasvir (VEL) and Ribavirin (RV). This meta-analysis was performed to outline the treatment response and efficacy of DAAV in HCV infected patients.

We systematically searched PubMed, Web of Science, MEDLINE, and Google Scholar for studies from January 2019 to December 2023. The studies selected met the criteria of patients having chronic HCV infection (genotype 3) and either compensated cirrhosis or decompensated chronic liver disease. Treatment regimens with DAAV specifically were included. The primary outcomes [sustained viral response (SVR), rapid virological response (RVR), end-of-treatment response (ETR)] were highlighted to assess treatment response.

The studies proved that the use of direct-acting antiviral agents in different combinations was very effective against HCV infection with minimal side-effects.

KEYWORDS: effectiveness, hepatitis C virus, meta-analysis, Sofosbuvir

INTRODUCTION:

Hepatitis C is a small, single-stranded RNA virus categorized within the hepacivirus family and the Flaviviridae genus. It is comprised of seven primary genotypes (1-7), each of which contains multiple sub-genotypes.1 According to epidemiological data, the prevalence of hepatitis C virus (HCV) shows 71 million people affected globally with a mortality rate of 3.5-5 million deaths annually. In Pakistan, the prevalence of hepatitis C was 8.2% in 2016,2 which has decreased to 6% in 2019.3 Province wise, the prevalence is 5.46% in Punjab, 2.55% in Sindh, 6.07% in Khyber Pakhtunkhwa, 25.77% in Balochistan, and 3.37% in federally administered tribal areas.4 Because of the disease’s great prevalence in the population, the source of disease transmission is being examined extensively in order to limit its progression. According to the literature, the hepatitis C virus is transmitted through infected blood, and common sources of spread include injections, transmission via infected blood transmission, use of infected needles and syringes, hospital transmission, and sharp instruments used in grooming as well as inadequate sterilization of medical equipment.5-9

Hepatitis C can cause acute or chronic cirrhosis in 10-20% of cases and hepatocellular cancer in 1.5%.10-15 In affected patients, 55-85% will progress to chronic HCV infection.16 Genotype 3 in particular, which is most prevalent in South Asia,17,18 is known to cause fibrosis and steatosis in some patients.19 In Pakistan the main genotype seen is genotype 3 with an occurrence rate of 67-87%.20,21 According to a recent study, HCV antibodies were found in 13.2 million youngsters.22 The patients had some laboratory investigations performed during selection, such as complete blood count (CBC) and liver function tests (LFTs).

As a treatment regime, Direct-Acting Antiviral Agents (DAAV) were approved by the FDA. Compared to previous pegylated interferon therapy, DAAV proved to have a better safety profile and improved results.23 The efficacy of these drugs was measured through sustained virological response (SVR) and rapid virological response (RVR). A review of
the last 30 years revealed that, for treatment-naive and non-cirrhotic patients, SVR rates of nearly 100% were possible with various DAA regimens; there is consensus in real-world and clinical data about GT-3, although geographical disparities in SVR rates continue.

Multiple studies conducted in different areas of Pakistan highlighted some of the drugs used in the treatment of Hepatitis C and their effects on the affected patients. One of the drugs is Sofosbuvir (SOF), which works as an HCV polymerase pyrimidine analogue. In a study conducted in Pakistan, out of 162 patients, high SVR and RVR were achieved after 8 weeks of therapy. For genotype 3 specifically, 100% SVR was achieved. Daclatasvir (DCV), an inhibitor of the virus also showed a good SVR according to a study conducted in Pakistan at Jinnah Hospital, Lahore. Another prominent drug is Velpatasvir (VEL), a non-structural protein 5A (NS5A) HCV protein inhibitor. A combination of this drug with sofosbuvir yielded exceptional results in patients without cirrhosis according to a study conducted in Khyber teaching hospital, Peshawar.

Adding ribavirin to DCV and SOF also proved effective according to a study in South Punjab. However, genotype 3 HCV patients showed better response compared to other genotypes. Treatment outcomes, however, also depend on patient factors such as age extent of liver disease.

This meta-analysis was performed to highlight the SVR and RVR rates of DAAV in different studies conducted in Pakistan.

METHODOLOGY:

1. Study Setting and Duration:
Studies published between January 2019 to December 2023 were considered for review. Only the studies that were performed in a hospital setting were included. The articles included in the review had various study designs, including observational studies, cohort studies, case-control studies, and randomized controlled trials (RCTs). The outcomes and results of the studies performed were essential in providing sufficient data for this meta-analysis.

2. Inclusion criteria:
Studies that were conducted in Pakistan between 2019-2023 were considered for this review. The inclusion criteria consisted of:
- Chronic HCV infection;
- Having genotype 3;
- Compensated cirrhosis (CC), and decompensated chronic liver disease (DCLD);
- Intervention used (SOF + DCV, SOF + VEL, SOF, ribavirin);
- Primary outcomes (SVR rate after either 12 or 24 weeks, RVR rate after either 4 or 8 weeks, ETR after 12 weeks);
- Study designs (real-world studies),
- Laboratory assessment, primarily HCV RNA PCR and others (such as: CBC, LFTs, RFTs, PT, INR, Serum Albumin, Fibro scan and Ultrasound abdomen).

3. Exclusion criteria:
The studies based on the following criteria were excluded from this meta-analysis:
- Patient with HCV infection of a genotype other than 3,
- Patients co-infected with hepatitis B,
- Relapsed or non-responding patients,
- Patients who were treated with drugs/combo combination of drugs other than (SOF + DCV, SOF + VEL, SOF, ribavirin).

Flow Chart showing selection process of studies
4. Data Analysis:
The data extracted from the selected studies were synthesized using meta-analysis techniques. To combine and analyse the data, we used a random-effects model through DerSimonian-Laird approach from JASP software. The pooled effect was calculated with a confidence interval of 95%. For heterogeneity between studies, $I^2$ statistics were used. The results are displayed in a forest plot.

RESULTS:
In a series of studies conducted in Pakistan between 2019 and 2023, the following significant findings have been observed in the context of hepatitis C treatment. i.e.:

§ Butt et al: Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi\textsuperscript{10}

§ Jawad et al: Safety and efficacy of Sofosbuvir therapy in chronic hepatitis C patients of Peshawar, Khyber Pakhtunkhwa\textsuperscript{25}

§ Khan et al: Efficacy of Daclatasvir with Sofosbuvir for Treating Chronic Hepatitis C Genotype 3\textsuperscript{26}

§ Waqas et al: Evaluation of Direct-Acting Antiviral Drugs for Hepatitis C Genotype 3 Patients from ages 30-50 years in Sialkot, Pakistan\textsuperscript{19}

§ Younas et al: Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients\textsuperscript{29}

The characteristic findings in each research are presented in the following tabulated form:

In the first study, led by Butt,\textsuperscript{10} the research unveiled an overall sustained virological response (SVR) rate of 88.3%. It's important to note that this response rate displayed variations among patients with distinct liver conditions. Specifically, those with Chronic Hepatitis C (CHC) showed a remarkable SVR of 95%, whereas patients with Compensated Cirrhosis (CC) had an 88% SVR, and individuals with Decompensated Chronic Liver Disease (DCLD) achieved an even higher SVR of 92%. Furthermore, the study reported an end of treatment response (ETR) rate of 97.33%, with variations across liver conditions as well, revealing an ETR of 98% in CHC, 98% in CC, and 95.8% in DCLD.

The second study, conducted by Jawad,\textsuperscript{25} demonstrated notable findings with a high SVR rate of 97%. Notably, patients with genotype 3 showed exceptional results with a 100% SVR. The ETR was equally impressive at 98.7%, with 100% ETR observed in genotype 3. The study also found a rapid virological response (RVR) of 94%, with genotype 3 showing an even higher RVR of 99%. Khan's\textsuperscript{26} study reported a SVR rate of 91.1%. Additionally, the ETR was 82.9%. It's important to note that the study examined ETR at different treatment durations, revealing an ETR of 74.8% at 4 weeks, which increased to 82.9% at 8 weeks. This suggests that treatment response rates improved with extended treatment durations.

<table>
<thead>
<tr>
<th>Place</th>
<th>Time</th>
<th>Sample Size</th>
<th>Study Design</th>
<th>Drug regimen used</th>
<th>Age</th>
<th>SVR</th>
<th>ETR</th>
<th>RVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Butt et al</td>
<td>JPMC, KHI</td>
<td>Jan 2019 -</td>
<td>300 (chc:200, CC:51,</td>
<td>SOF/DCV/RV</td>
<td>&gt;12</td>
<td>88.3% (95% in CHC,</td>
<td>97.33% (98% in CHC,</td>
<td>94% (99% gen 3)</td>
</tr>
<tr>
<td></td>
<td>dec 2020</td>
<td></td>
<td>DCLD:49)</td>
<td></td>
<td>yr.</td>
<td>88% in CC and 92% in DCLD)</td>
<td>98% in CC and 95.8% in DCLD</td>
<td></td>
</tr>
<tr>
<td>Jawad et al</td>
<td>Khyber Teaching</td>
<td>April to</td>
<td>162</td>
<td>SOF</td>
<td>20-68</td>
<td>97% (100% in gen 3)</td>
<td>98.7% (100% gen 3)</td>
<td>94% (99% gen 3)</td>
</tr>
<tr>
<td></td>
<td>hospital, Peshawar</td>
<td>June 2018</td>
<td></td>
<td></td>
<td>yr.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Khan et al</td>
<td>Hepatitis Clinic,</td>
<td>Jan 2019 to</td>
<td>135</td>
<td>SOF /DCV</td>
<td>18-80</td>
<td>91.1%</td>
<td>82.9</td>
<td>4wks:74.8%</td>
</tr>
<tr>
<td></td>
<td>Medical Unit–II,</td>
<td>June 2019.</td>
<td></td>
<td></td>
<td>yr.</td>
<td></td>
<td></td>
<td>8wks:82.9%</td>
</tr>
<tr>
<td></td>
<td>Jinnah Hospital,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lahore</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waqas et al</td>
<td>Sialkot, Pakistan</td>
<td>Issued on</td>
<td>228 (177 gen 3)</td>
<td>SOF/DCV/VEL</td>
<td>30-50</td>
<td>90%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dec 2022</td>
<td></td>
<td></td>
<td>yr.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Younas et al</td>
<td></td>
<td>January to</td>
<td>229 (216 gen 3)</td>
<td>SOF/DCV</td>
<td>18-75</td>
<td>93% (92.6% in gen 3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>August 2018</td>
<td></td>
<td></td>
<td>yr.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Waqa’s study found an overall SVR rate of 90%, though it did not specify variations based on liver conditions or genotypes.

Lastly, Younus’s study reported a high SVR of 93%. Notably, patients with genotype 3 achieved a slightly lower but still impressive SVR of 92.6%.

These valuable findings can be seen in the forest plot plotted below, offering a comprehensive overview of the treatment response rates.

The overall SVR was calculated to be 91.8% (95% CI: 88.53-95.23%). The I² statistics calculated a value of 99.9%, showing high heterogeneity among the studies.

**Treatment Efficacy:**

1. Sofosbuvir/Daclatasvir: The Sofosbuvir/Daclatasvir regimen achieved a mean sustained virological response (SVR) rate of 90.6% across the studies. The SVR rates ranged from 90% to 97.33%.

2. Sofosbuvir/Velpatasvir/Daclatasvir: The regimen demonstrated a mean SVR rate of 90%.

3. Sofosbuvir/Ribavirin/Daclatasvir: The regimen yielded an SVR rate of 88.33%.

4. Sofosbuvir: This regimen alone yielded SVR rate of 97%.

**Genotype Specificity:**

Genotype 3 was the most prevalent genotype among the study participants, with varying responses to different regimens. Sofosbuvir/Velpatasvir consistently demonstrated high efficacy in treating genotype 3, with SVR rates reaching up to 90%. Sofosbuvir/Daclatasvir also showed effective outcomes against genotype 3, with SVR rate of 92.9%. Sofosbuvir regimen alone achieved SVR of 100% in genotype 3.

**DISCUSSION:**

Chronic HCV infection is mostly asymptomatic. Hepatitis C has the potential to result in acute or chronic cirrhosis in approximately 10-20% of cases and may lead to hepatocellular carcinoma in about 1.5% of instances. Notably, genotype 3, which is highly prevalent in Pakistan, is recognized for its tendency to cause fibrosis and steatosis in certain individuals. Recent research indicates that HCV antibodies were detected in 13.2 million young individuals. During the patient selection process, various laboratory tests, including complete blood count (CBC) and liver function...
tests (LFTs), were conducted.

Waqas et al achieved a remarkable pooled SVR rate of over 90% for HCV genotype 3 patients aged 30-50 using the SOF/DCV/VEL regimen. This impressive outcome aligns closely with the findings in study done in Year 2020 in Pakistan, which reported an overall SVR rate of 95.5%.

Similarly, another study exhibited rapid viral load reduction, with 91% of patients achieving PCR negativity after four weeks, and a corresponding SVR12 rate of 85.5%, mirroring the robust results seen in the Sialkot study. Moreover, another research displayed compelling efficacy, with a 98.9% end-of-treatment response and a strong SVR of 95.8%, emphasizing the regimen’s potency, akin to the findings observed in the Sialkot study. These parallels underscore the uniformity in outcomes and reinforce the notion that the SOF/DCV/VEL regimen consistently delivers potent results in treating HCV genotype 3 patients.

Much like the Butt et al study, which reported an impressive 88.3% SVR rate across all genotypes with the SOF/DCV/RV regimen, several other studies have produced parallel results. Another study, focusing on patients with chronic hepatitis C genotype 3, demonstrated that both SOF/RBV and SOF/DCV±RBV regimens yielded similar SVR12 rates, achieving an overall SVR of 91.9%. The addition of ribavirin to the combination is also recommended by the European association for study of liver (EASL), showing its effectiveness is further supported by studies outside Pakistan as well. This emphasizes the potency of these regimens in their respective contexts, mirroring the broad effectiveness observed in the Karachi study. Moreover, one other study, achieving an outstanding 98.7% response rate at the end of treatment and a 97% SVR in genotype 3 patients, reaffirms the robust performance of the SOF/DCV/RV regimen, consistent with the Butt et al study’s results. Furthermore, another study found that treatment with 400 mg of sofosbuvir plus 100 mg of velpatasvir for 12 weeks was both well-tolerated and highly effective, aligning with the consistent notion that these regimens offer potent and broadly effective treatment options for chronic HCV across various genotypes.

Using a SOF-based regimen is linked to poorer outcomes (lower SVRs) in cases of advanced liver disease. These patients have a higher chance of developing HCC and cirrhosis problems even after receiving therapy. Even when clinical and laboratory results improve, these concerning characteristics still need to be constantly monitored.

The Younus et al study revealed a substantial 93% SVR rate, with the SOF/DCV regimen demonstrating a 92.6% efficacy rate across genotype 3, showcasing the effectiveness of this treatment along with Khan et al, showing SVR of 91.1% with SOF/DCV therapy. In a parallel vein, study conducted in Pakistan, reported an outstanding ETR of 98.9% and a strong SVR of 95.8%, endorsing the efficacy of the Sofosbuvir and Daclatasvir combination. Additionally, another study conducted in 2020 highlighted a noteworthy overall SVR rate of 95.5%. Patients who progressed to liver fibrosis as a result of HCV also showed regression with this combination therapy according to the results of another study.

Regarding side-effects, a study conducted in Lahore, Pakistan reported fatigue, arthritis, headache, loss of appetite and anemia in patients undergoing therapy. However, it also noted that patients who were taking a combination of Sofosbuvir and Velpatasvir experienced more side effects compared to patients on Sofosbuvir and Daclatasvir combination. When compared to the previous regimen of interferon therapy, the side-effects were significantly lesser overall of direct-acting antiviral drugs.

CONCLUSION:

The combined results of these studies conclude that direct-acting antiviral agents, particularly the SOF/VAL and SOF/DCV regimens, were very effective and had good safety profiles in chronic Hepatitis C virus infection. Genotype 3, particularly common in Pakistan, showed great response to the drugs. The results conclude that choosing not only the appropriate agents but setting the correct regimen is vital for the best possible treatment that can be achieved against Hepatitis C infection in Pakistan. All the findings are valuable in the ongoing attempt to curb the prevalence of the disease in this region.


06. Abbas: Prevalence and mode of spread of hepatitis... - Google Scholar [Internet]. [cited 2023 Oct 28].

07. Aslam: Association between smallpox vaccination and... - Google Scholar [Internet]. [cited 2023 Oct 28].

08. High prevalence of hepatitis C virus infection in the largest province of Pakistan - IDREES - 2008 - Journal of Digestive Diseases - Wiley Online Library [Internet]. [cited 2023 Oct 28].


Meta-Analysis of the Effectiveness of Sofosbuvir-Based Regimens in Treating Hepatitis C Genotype 3

30. The natural course of HCV infection and the need for treatment [Internet]. [cited 2023 Oct 16].


